Biosensor Gap Impedance for Tau Protein Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease, particularly through quantitative analysis of tau proteins, lack precision due to individual variations and fail to accurately differentiate between normal and diseased samples, necessitating a more reliable approach for monitoring post-translational modifications.
Innovation Solution
A system utilizing a biosensor with a nanogap configuration, measuring impedance changes caused by antibodies binding to phosphorylated and O-glycosylated tau proteins, calculates a change rate of impedance to assess the degree of post-translational modifications, enabling accurate disease progression evaluation and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If quantitative analysis of tau proteins is used for diagnosis, then measurement capability is provided, but measurement precision is insufficient due to individual variations
Solution Approach 1:
The patent changes the measurement parameter from absolute tau protein quantity to the ratio of phosphorylated tau to total tau proteins. This parameter transformation resolves the contradiction by providing a relative measure that accounts for individual variations in total protein levels, thereby improving both measurement precision and diagnostic reliability.
Solution Approach 2:
The patent introduces an intermediary approach by using multiple antibodies that specifically recognize different phosphorylation sites of tau proteins. These antibodies act as intermediaries to detect and quantify specific phosphorylated forms of tau, enabling precise measurement of post-translational modification states rather than total protein amounts.
2Measurement precision
If conventional ELISA methods are used, then protein quantification is achieved, but sensitivity and specificity are insufficient to distinguish normal and diseased samples
Solution Approach 1:
The patent segments the ELISA process into parallel measurement channels: one for total tau protein and another for phosphorylated tau protein. By segmenting the measurement into separate specific assays, the method achieves high sensitivity and specificity for detecting disease markers while maintaining manageable manufacturing complexity through standardized assay protocols.
Solution Approach 2:
The patent applies local quality by using antibodies with specific recognition characteristics tailored to different tau protein forms. The first antibody specifically targets phosphorylated tau while the second targets total tau, creating localized detection specificity that enables accurate differentiation between normal and diseased states.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable method for distinguishing between normal and diseased samples by quantifying the risk level and progression rate of Alzheimer's disease, overcoming the limitations of conventional ELISA methods with improved sensitivity and specificity.
Implementation Method 1
measuring an impedance of a sample introduced into a sensor and calculating a change rate of the measured impedance
Data Source
AI summary
The present disclosure relates to a system for monitoring post-translational modification of protein using a biosensor with a gap, which performs with high reliability a diagnosis of a disease associated with a target protein for which impedance is measured, by measuring an impedance of a sample introduced into a sensor and calculating a change rate of the measured impedance, and to a method of manufacturing the biosensor used for the system.